Dianthus Therapeutics 320% Year: What Investors Should Know as Stakes Shift
Dianthus Therapeutics has surged 320% over the past year, even as a large investor reduced its stake. This article di...
Compare index fund performance year by year to detect stability, volatility, and opportunities for strategic adjustments.
25,004 articlesDianthus Therapeutics has surged 320% over the past year, even as a large investor reduced its stake. This article di...
When a high-profile artist steps away for health, the financial ripple is real—not just for the performer, but for sp...
Gold has emerged as a standout performer in 2026, with certain bullion-backed ETFs delivering resilience and steady g...
Is Elon Musk steering his empire toward semiconductors? This article explores how Musk’s ventures touch chips, what t...
A major institutional stake in TTMI has sparked fresh debates about the stock's risk and reward. This guide breaks do...
The spotlight in AI investing is shifting from screens to factories. The BOTZ ETF is positioning itself to ride a wav...
A disciplined $500 monthly investment into a semiconductor-focused ETF since 2016 would have climbed to roughly half ...
A new period of market volatility and plan underfunding concerns spotlight four retirement mistakes that cost electri...
Institutional moves can reshape a niche tech stock overnight. This article breaks down the recent liquidation by Loun...
The memory ETF DRAM fell 15% in one day as a guidance miss sparked a broader selloff, underscoring the risk of a conc...
A hedge fund quietly doubled down with an $8 million bet as euronet stock tanked this past year. Here’s what that mov...
An emerging markets high dividend ETF is delivering a standout yield for income-focused investors, but the strategy c...